Zealand Pharma shares fell as much as 26% on Monday following the release of new safety data from a late-stage study of its experimental weight loss drug, survodutide [1]. The Danish pharmaceutical company reported that while survodutide met its primary efficacy targets, significant safety concerns emerged: 19% of patients in the treatment group discontinued the study due to gastrointestinal events, compared to only 2.9% in the placebo group [1]. More than 40% of patients reported vomiting, raising further questions about the drug's tolerability and commercial viability [1].
Barclays analysts highlighted that 'safety/tolerability remains the key issue,' and warned that the high discontinuation rate could limit survodutide's potential as a treatment for obesity or fatty liver disease [1]. Citi analysts echoed these concerns, stating that a 19% discontinuation rate due to adverse events is significant, and that the incidence of nausea, vomiting, diarrhea, and constipation is higher than what is considered commercially viable compared to rival drugs such as tirzepatide and semaglutide [1].
The market reacted sharply to the news, with Zealand Pharma shares last seen down 24%, compounding a nearly 50% decline year-to-date [1]. This latest setback comes about three months after Zealand stock experienced its worst day on record, when another experimental anti-obesity drug from the company disappointed investors with lower-than-expected weight loss results [1].
No forward-looking statements from the company were included in the article, but analyst commentary suggests ongoing skepticism about the commercial prospects for survodutide given the safety profile revealed in the latest data [1].
CONCLUSION
Zealand Pharma's latest trial results for survodutide have raised significant safety concerns, leading to a sharp decline in its share price. Analysts warn that the high rate of adverse events and patient discontinuations could severely limit the drug's commercial potential, especially against established competitors. The market's negative reaction underscores investor uncertainty about the company's obesity drug pipeline.